Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

The recommendation received an A grade, meaning it is well supported by scientific evidence. This is important because the Affordable Care Act (ACA) requires private insurers to cover preventive services recommended by the US Preventive Services Task Force with an “A” or “B” rating. The task force also released a recommendation for routine HIV screening for people ages 15 to 65 and for all pregnant women, also with an “A” grade.

June 11, 2019

PrEP use among adults may significantly reduce HIV prevalence among MSM and may also have significant downstream effects on HIV incidence among adolescents; PrEP targeting adolescents remains an important intervention for HIV prevention.

May 22, 2019
PLoS One

Pre-exposure prophylaxis (PrEP) for HIV prevention has become more well-known and has perhaps sparked more interest among men who have sex with men (MSM), meaning the percentage of at-risk women taking PrEP is unfortunately lagging. This is not only because women are unaware of PrEP; many providers lack knowledge of PrEP as well.

May 16, 2019
Contagion Live

Gilead Sciences announced Wednesday that a generic version of Truvada will be available in September 2020, one year earlier than expected. "Gilead reached an agreement with Teva Pharmaceuticals in 2014 to allow the early launch of a generic version of Truvada into the market in 2020, a year earlier than required," wrote Douglas Brooks, Gilead's executive director for community engagement, in an email shared with NBC News by the advocacy group PrEP4All.

May 8, 2019
NBC News

In this article, we overview current U.S. and Canadian PrEP guidelines and provide explicit guidance about how nurses can provide PrEP, including the clinical pathways and medical directives we use in our clinic. We call nurse-led provision of PrEP, PrEP-RN (Pre-Exposure Prophylaxis–Registered Nurse) and feel it may be an important step forward in HIV prevention.

April 1, 2019
Journal of the Association of Nurses in AIDS Care
Subscribe to RSS - PrEP